|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE)-Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute.
The preliminary, promising scientific data were presented at the biannual HEP DART meeting last December, where it was recognized as one of the best new therapies / novel strategies at the conference. Jon Cohen of Science magazine tweeted "Intriguing novel mechanism for attacking Hepatitis B virus . "Https://twitter.com/sciencecohen/status/1204891529275269120
Dr. Carol L. Brosgart, a recent addition to the Enochian Board of Directors said, "I began my medical and research career in the field of public health in the late 70's, prior to the development of clinical laboratory tests for Hepatitis B and the Hepatitis B vaccine. At that time, there were no therapies for Hepatitis B. Since that time, I have overseen the development and licensure of several major therapies for the treatment of Hepatitis B and HIV. With recent advances in our ability to cure Hepatitis C , there is a new focus on finding curative regimens for both Hepatitis B and HIV. I am very excited by this innovative approach and its potential to become an effective treatment or cure for Hepatitis B. "
On November 25, Enochian announced that it was expanding its infectious diseases pipeline by entering into an agreement in principle to acquire the exclusive license from SRI. |
|
发表于 2020-2-4 11:44